{"title": "An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus", "doi": "10.1101/2020.03.19.997890", "citation_id": "2020.03.19.997890v1", "date": "2020-03-20", "laguage": "en", "journal_title": "bioRxiv", "first_page": "2020.03.19.997890", "abstract": "<p>Coronaviruses (CoVs) traffic frequently between species resulting in novel disease outbreaks, most recently exemplified by the newly emerged SARS-CoV-2. Herein, we show that the ribonucleoside analog Beta-D-N4-hydroxycytidine (NHC, EIDD-1931) has broad spectrum antiviral activity against SARS-CoV 2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs, as well as increased potency against a coronavirus bearing resistance mutations to another nucleoside analog inhibitor. In mice infected with SARS-CoV or MERS-CoV, both prophylactic and therapeutic administration of EIDD-2801, an orally bioavailable NHC-prodrug (Beta-D-N4-hydroxycytidine-5[9]-isopropyl ester), improved pulmonary function, and reduced virus titer and body weight loss. Decreased MERS-CoV yields in vitro and in vivo were associated with increased transition mutation frequency in viral but not host cell RNA, supporting a mechanism of lethal mutagenesis. The potency of NHC/EIDD-2801 against multiple coronaviruses, its therapeutic efficacy, and oral bioavailability in vivo, all highlight its potential utility as an effective antiviral against SARS-CoV-2 and other future zoonotic coronaviruses.</p>", "twitter_description": "Coronaviruses (CoVs) traffic frequently between species resulting in novel disease outbreaks, most recently exemplified by the newly emerged SARS-CoV-2. Herein, we show that the ribonucleoside analog Beta-D-N4-hydroxycytidine (NHC, EIDD-1931) has broad spectrum antiviral activity against SARS-CoV 2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs, as well as increased potency against a coronavirus bearing resistance mutations to another nucleoside analog inhibitor. In mice infected with SARS-CoV or MERS-CoV, both prophylactic and therapeutic administration of EIDD-2801, an orally bioavailable NHC-prodrug (Beta-D-N4-hydroxycytidine-5[']-isopropyl ester), improved pulmonary function, and reduced virus titer and body weight loss. Decreased MERS-CoV yields in vitro and in vivo were associated with increased transition mutation frequency in viral but not host cell RNA, supporting a mechanism of lethal mutagenesis. The potency of NHC/EIDD-2801 against multiple coronaviruses, its therapeutic efficacy, and oral bioavailability in vivo, all highlight its potential utility as an effective antiviral against SARS-CoV-2 and other future zoonotic coronaviruses.", "full_text_html_url": "https://www.biorxiv.org/content/10.1101/2020.03.19.997890v1.full", "public_url": "https://www.biorxiv.org/content/10.1101/2020.03.19.997890v1", "abstract_html_url": "https://www.biorxiv.org/content/10.1101/2020.03.19.997890v1.abstract", "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/03/20/2020.03.19.997890.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/", "publisher": "Cold Spring Harbor Laboratory", "pisa": "biorxiv;2020.03.19.997890v1", "access_rights": "restricted", "authors": ["Timothy P Sheahan", "Amy C Sims", "Shuntai Zhou", "Collin Hill", "Sarah R Leist", "Alexandra Schaefer", "Maria Agostini", "Andrea Pruijssers", "Ariane J Brown", "Gregory Bluemling", "Michael Natchus", "Manohar Saindane", "Alexander Kolykhalov", "George Painter", "Ronald Swanstrom", "Kenneth Dinnon", "Rachel Graham", "Jennifer Harcourt", "Azaibi Tamin", "Natalie J. Thornburg", "Stephanie A. Montgomery", "James Chappell", "Mark Denison", "Ralph S. Baric"]}